ஜா ஆய்வகம் முன்னோக்கி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜா ஆய்வகம் முன்னோக்கி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜா ஆய்வகம் முன்னோக்கி Today - Breaking & Trending Today

Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology

Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , Karen Akinsanya , Dburns Mcclellan , Alan Sandler , Jaren Irene Madden , Mike Zanoni , Billy Cho , Ryo Imai Robert Flamm , Exchange Commission On , Zai Lab Contacts , Zai Lab , Zai Lab Nasdaq , Exchange Commission , Zai Lab Limited Nasdaq , Zai Lab Forward , Zai Lab Limited , Forward Looking Statements , Private Securities Litigation Reform Act , Quarterly Report , Irene Madden , Ryo Imai , Robert Flamm , ஒன்றுபட்டது மாநிலங்களில் , தீக்காயங்கள் ம்க்க்லெல்யாந் , ஆலன் சாண்ட்லர் , ஜாரேன் ஐரீந் மேடன் ,

Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China

/PRNewswire/ Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an. ....

Hong Kong , Robert Flamm , Ryo Imai , Mike Zanoni , Billy Cho , Temre Johnson , Dburns Mcclellan , Priyanka Shah , Charlesm Baum , Zai Lab Contacts , Zai Lab , World Health Organization , Zai Lab Limited , Mirati Therapeutics Inc , Exchange Commission , Zai Lab Forward , Mirati Therapeutics , Greater China , Colorectal Cancer , Private Securities Litigation Reform Act , ஹாங் காங் , ராபர்ட் ப்லம்ம் , மைக் ஜஞோநி , பில்லி சோ , தீக்காயங்கள் ம்க்க்லெல்யாந் , பிரியாங்க ஷா ,

Zai Lab Announces Financial Results for Second-half and Full-year 2020

Zai Lab Announces Financial Results for Second-half and Full-year 2020
March 01, 2021 07:00 ET
| Source:
Zai Lab Limited
Zai Lab Limited
Company to Host Conference Call and Webcast Today at 8:00 a.m. ET
SHANGHAI and SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today reported financial results for the second half and full year of 2020, along with corporate updates.
“2020 was another year of great accomplishment for Zai Lab,” said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. “We successfully launched ZEJULA for both second-line and first-line ovarian cancer and Optune for glioblastoma in China. We submitted NDAs and were granted priority reviews by China’s National Medical Products Administration (NMPA) for both QINLOCK for advanced gastrointestinal stromal tumors (GIST) and NUZY ....

United States , United Kingdom , Hong Kong , Dburns Mcclellan , Mike Zanoni , Alan Sandler , Optune Lua , Billy Cho , Ryo Imai Robert Flamm , Zai Lab , Zai Lab Limited , China National Medical Products Administration , European Union , Zai Lab Forward , Society For Immunotherapy Of Cancer , Drug Administration , Zai Lab Annual Report On Form , Company To Host Conference Call , China National Healthcare Security Administration , Exchange Commission , Hong Kong Department Of Health , National Reimbursement Drug List , Head Of Global Development , Business Development , Host Conference Call , Webcast Today ,

Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China's National Reimbursement Drug List

[December 28, 2020]
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China s National Reimbursement Drug List
SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULAÂ® has been included in the updated National Reimbursement Drug List (NRDL) released by Chinaâs National Healthcare Security Administration (NHSA). ZEJULA (niraparib) is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor with national Category 1 designation. It has been included in the NRDL as maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. ....

Dburns Mcclellan , Mike Zanoni , Billy Cho , William Liang , Ryo Imai Robert Flamm , Zai Lab , Zai Lab Limited , Zai Lab Annual Report On Form , China National Healthcare Security Administration , Exchange Commission , National Reimbursement Drug List , Zai Lab Announces Inclusion , China National Reimbursement Drug List , Zai Lab Forward , Lab Announces Inclusion , National Reimbursement Drug , Lab Limited , National Healthcare Security Administration , Chief Executive Officer , Chief Commercial , About Zai , Greater China , Private Securities Litigation Reform Act , Annual Report , Ryo Imai , Robert Flamm ,

Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for .
Zai Lab LimitedDecember 28, 2020 GMT
- Zai Lab to lead development and commercialization of CLN-081 in Greater China
- Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties
- Zai Lab to join ongoing global trial for CLN-081
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 28, 2020 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Cullinan Oncology, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, today announced an exclusive license agreement for the development, manufacturing and commercialization of CLN-081 in Greater China. ....

United Kingdom , Hong Kong , Mike Zanoni , Billy Cho , Jeff Trigilio , Ryo Imai Robert Flamm , Matt Burke , Dburns Mcclellan , Rowen Hughes , Cullinan Pearl , Exchange Commission , Zai Lab , Cullinan Oncology , Zai Lab Limited , Zai Lab Annual Report On Form , Zai Lab Forward , Lab Limited , Greater China , Chief Executive Officer , Private Securities Litigation Reform Act , Annual Report , Ryo Imai , Robert Flamm , ஒன்றுபட்டது கிஂக்டம் , ஹாங் காங் , மைக் ஜஞோநி ,